NEW YORK – The European Commission (EC) on Monday granted marketing authorization to AbbVie's Elahere (mirvetuximab soravtansine) as a new therapy option for previously treated patients with folate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback